Meeting
2023 ASCO Annual Meeting
Association of CDK4 amplification with duration of response to bevacizumab in glioblastoma.
Authors
John L. Villano
University of Kentucky, Lexington, KY
John L. Villano , Rachael M Morgan , Shulin Zhang , Jill Kolesar , Joanne Xiu , Hilary Seifert , Theodore Nicolaides , Stephanie Rock , Santosh Kesari , Sonikpreet Aulakh , Eric T. Wong , Michael J. Glantz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2026)
DOI
10.1200/JCO.2023.41.16_suppl.2026
Abstract #
2026
Poster Bd #
383
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Individualized screening trial of innovative glioblastoma therapy (INSIGhT).
First Author: Brian Michael Alexander
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tumor genomics and sidedness to predict outcomes in metastatic colorectal cancer (mCRC).
First Author: Patrick M Boland
Poster
2023 ASCO Breakthrough
Personalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing.
First Author: Aki Morikawa
Poster
2023 ASCO Annual Meeting
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
First Author: Se-Hoon Lee